Table 3 Grade 3 or 4 adverse events (safety population)
Treatment-emergent | No | Eltrombopag | Eltrombopag | Eltrombopag |
|---|---|---|---|---|
Eltrombopag | 75 mg | 100 mg | 150 mg | |
(n = 3)a | (n = 7) | (n = 4) | (n = 1) | |
Hematologic AEs, n (%) | ||||
Thrombocytopenia | 0 | 3 (43) | 2 (50) | 1 (100) |
Neutropenia | 2 (67) | 4 (57) | 4 (100) | 0 |
Anemia | 0 | 3 (43) | 2 (50) | 0 |
Leukopenia | 0 | 3 (43) | 0 | 0 |
Febrile neutropenia | 0 | 2 (29) | 0 | 0 |
Nonhematologic AEs, n (%) | ||||
Pulmonary embolism | 1 (33) | 0 | 0 | 0 |
Abdominal abscess | 1 (33) | 0 | 0 | 0 |
Abdominal pain | 0 | 1 (14) | 0 | 0 |
Mucosal inflammation | 0 | 1 (14) | 0 | 0 |
Dehydration | 0 | 1 (14) | 0 | 0 |
Subclavian vein thrombosis | 0 | 1 (14) | 0 | 0 |
Sepsis | 0 | 0 | 1 (25) | 0 |